Recursion Tops Q3 Revenue Estimates and Extends Cash Runway Into 2029
RXRX sits 38% above its 52-week low of $2.77.
Summary
Recursion beat Q3 revenue estimates with $18.6 million versus $14.8 million expected, narrowed its net loss to $119.0 million, and extended its cash runway into 2029. New REC-4881 data across the GI tract and a Sanofi development candidate milestone support a registrational trial planned for the second half of 2027.
Key Events · Earnings and Guidance · RXRX
-
Q3 Revenue Beats Consensus
Total revenue came in at $18.6 million versus $14.8 million expected, up from $5.2 million a year ago, driven by a $10.0 million Sanofi milestone.
-
Cash Runway Extended Into 2029
Cash was $561.5 million at September 30, 2026; pro forma for $187.2 million in net October offering proceeds it was about $748.7 million. Guidance is under $375 million cash operating expense for 2026 and under $360 million for 2027.
-
REC-4881 Shows Activity Across GI Tract
87% of patients had total polyp burden reductions with a 47% median reduction; 82% had lower GI reductions and 6 of 8 patients with polyps over 5 mm saw fewer of them. A registrational trial is planned for the second half of 2027 pending FDA discussions.
-
Sanofi Options First Development Candidate
The option triggered a $10 million milestone, bringing total Sanofi inflows to $144 million, with more than $300 million in additional milestones possible plus double-digit royalties.
Analysis · RXRX · Life Sciences
Revenue of $18.6 million beat the $14.8 million consensus, and the loss narrowed to $119.0 million from $162.3 million a year ago. Cash stood at $561.5 million at quarter-end, or roughly $748.7 million pro forma for the October offering, and management now says funding lasts into 2029 while holding 2026 cash operating expense below $375 million and guiding 2027 below $360 million. The clinical update matters as much as the numbers: REC-4881 now shows polyp reductions across both upper and lower GI tracts, including larger high-risk polyps, with a registrational trial planned for the second half of 2027 pending FDA talks. Sanofi optioning its first development candidate adds a $10 million milestone and takes total Sanofi inflows to $144 million. Fred Hassan taking the chair adds operating and commercialization experience as the company moves toward late-stage development.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RXRX was trading at $3.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $2.77 to $5.76. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.